Chronic versus episodic migraine: The 15‐day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency

Abstract

Objective: To evaluate whether the 15-day threshold of headache days per month adequately reflects substantial differences in disability across the full spectrum of migraine. Background:The monthly frequency of headache days defines migraine subtypes and has crucial implications for epidemiological and clinical research as well as access to care. Methods: The patients with migraine (N = 836) who participated in the American Registry for Migraine Research, which is a multicenter, longitudinal patient registry, between February 2016 and March 2020, were divided into four groups based on monthly headache frequency: Group 1 (0-7 headache days/month, n = 286), Group 2 (8-14 headache days/month, n = 180), Group 3 (15-23 headache days/month, n = 153), Group 4 (≥24 headache days/month, n = 217). Disability (MIDAS), Pain intensity (NRS), Work Productivity and Activity Impairment (WPAI), Pain Interference (PROMIS-PI), Patient Health Questionnaire-4 (PHQ-4), and General Anxiety Disorder-7 (GAD-7) scores were compared. Results: Mean (standard deviation [SD]) age was 46 (13) years (87.9% [735/836] female). The proportion of patients in each group was as follows: Group 1 (34.2% [286/836]), Group 2 (21.5% [180/836]), Group 3 (18.3% [153/836]), and Group 4 (26.0%[217/836]). There were significant relationships with increasing disability, lost productive time, and pain interference in higher headache frequency categories. There were no significant differences between Group 2 and Group 3 for most measures (NRS, all WPAI scores, PROMIS-PI, GAD-7, and PHQ-4), although MIDAS scores differed (median [interquartile range (IQR)]; 38 [20-58] vs. 55 [30-90], p < 0.001). Patients in Group 1 had significantly lower MIDAS (median [IQR];[16][17][18][19][20][21][22][23][24][25][26][27][28][29][30], p < 0.001), WPAI-% total active impairment (mean (SD): Group 1 [30.9 (26.8)] vs. Group 2 [39.2 (24.5), How to cite this article: Ishii R, Schwedt TJ, Dumkrieger G, et al. Chronic versus episodic migraine: The 15-day threshold does not adequately reflect substantial differences in disability across the full spectrum of headache frequency.

Galcanezumab effect on “whole pain burden” and multidimensional outcomes in migraine patients with previous unsuccessful treatments: a real-world experience

“…Migraine is recognized as the second-highest cause of years lived with disability, the first in patients aged between 15 and 49 years [ 23 ] and undertreatment strongly affect migraine related disability, especially in patients with high frequency or chronic migraine [ 24 – 26 ]. Therapeutic approach to these patients involves the use of preventive strategies based, until few years ago, only on “repositioning drugs” characterized by unsatisfactory responses but, above all, by non-excellent tolerability profiles strongly affecting patients’ adherence to treatment [ 3 , 27 , 28 ].…”

Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort study

“…Consecutive patients diagnosed with episodic migraine with high-frequency (HFEM, i.e., 8–14 monthly migraine days, MMDs [ 10 , 11 ]) or CM (1.3 ICHD-3 [ 12 ]), treated with mAbs anti-CGRP (erenumab or galcanezumab) from November 2019 to July 2021 according to clinical indication [ 13 , 14 ], were considered. They were not previously involved in any randomized clinical mAbs anti-CGRP trial.…”

The impact of pre‐morbid headaches on headache features and long‐term health outcomes following traumatic brain injury: Insights from the American Registry for Migraine Research

“…[21][22][23] There are several prior analyses that have included ARMR data and that might have included patients in this analysis. [24][25][26][27][28][29][30]…”